Publications

A Novel 2-Metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT.

Cancers · 2022 · DOI: 10.3390/cancers14123031

Patil, S., et al. (2022). "A Novel 2-Metagene signature to identify high-risk HNSCC patients." Cancers, 14(12), 3031.

Developed a novel 2-metagene signature for risk stratification in head and neck squamous cell carcinoma (HNSCC) patients receiving postoperative radiotherapy, enabling personalized treatment decisions.